Progress in ALS science and therapeutic development
Latest news
Read our latest announcements on AP-101
December 05, 2025
AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study
September 25, 2025
AL-S Pharma Appoints Internationally Recognized Neurologist and Clinical Trial Expert Prof. Dr. Angela Genge as Chief Medical Officer
September 04, 2025
AL-S Pharma Announces Positive Topline Results From Phase 2 Study of AP-101 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Upcoming events
We regularly participate in scientific conferences, partnering forums, and industry
meetings. Stay up to date on where you can meet us.